Shots:

• The P-II BLAZE-1 study involves assessing of LY-CoV555 and LY-CoV01 for symptomatic COVID-19 in the outpatient setting. The trial enrolled mild-to-moderate recently diagnosed COVID-19 patients across four groups i.e. LY-CoV555 (700mg/2800mg/7000 mg) vs PBO
• The 1EPs i.e. change from baseline in viral load @11days was met with 2800mg dose level- but not the others. LY-CoV555 showed a positive impact on COVID-19-related hospitalization or ER visit (1.7% vs 6%) relating to a 72% risk reduction in this limited population- no patients progressed to mechanical ventilation or died- rate of resistance variants (8% vs 6%)
• LY-CoV555 is a potent- neutralizing IgG1 mAb targeting the spike protein of SARS-CoV-2 and is well tolerated with no AEs. The BLAZE-1 study is ongoing with additional treatment arms

­ Ref: PRNewswire | Image: Eli Lilly